Infections complicating mycosis fungoides and Sézary syndrome
- PMID: 1740857
Infections complicating mycosis fungoides and Sézary syndrome
Abstract
Objective: To determine, in patients with mycosis fungoides and Sézary syndrome, the incidence of infections, the importance of nosocomial infections, and the epidemiologic factors associated with cutaneous and visceral infections.
Design and setting: Retrospective inception cohort study at a university medical center referral clinic.
Patients: Three hundred fifty-six patients with mycosis fungoides or Sézary syndrome.
Main outcome measures: Incidence rates for specific infections, and multivariate risk ratios for demographic and clinical factors associated with infection.
Results: Cutaneous bacterial infection was most common (17.0 infections per 100 patient-years), followed by cutaneous herpes simplex virus and herpes zoster virus infection (3.8 infections per 100 patient-years), bacteremia (2.1 infections per 100 patient-years), bacterial pneumonia (1.7 infections per 100 patient-years), and urinary tract infection (1.4 infections per 100 patient-years). Twenty-seven percent of herpesvirus infections disseminated on the skin but none disseminated to internal organs. Pneumonia or bacteremia was present in 88% of patients who died of infection. Only three patients had invasive fungal or protozoal infection. Nosocomial infections accounted for 19% of cutaneous bacterial infections, 59% of bacteremias, 62% of pneumonias, and 88% of infections leading to death. By logistic and Cox regression, the presence of extracutaneous involvement with lymphoma was the most important independent risk factor for recurrent bacterial skin infection (risk ratio [RR], 12; 95% confidence interval [CI], 1.2 to 120), disseminated herpesvirus infection (RR, 28; 95% CI, 2.7 to 290), bloodstream infection (RR, 5.5; 95% CI, 1.7 to 18), and death from infection (RR, 15; 95% CI, 3.6 to 64).
Conclusions: Community-acquired bacterial skin infections are a common cause of morbidity in patients with mycosis fungoides and Sézary syndrome but are usually treated without hospital admission. Bacteremia and pneumonia, which are usually nosocomial, are the major infectious causes of death. Advanced disease stage, independent of corticosteroids and other therapies, is the most important risk factor for both cutaneous and systemic infections.
Similar articles
-
Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.Arch Dermatol. 2003 Jul;139(7):857-66. doi: 10.1001/archderm.139.7.857. Arch Dermatol. 2003. PMID: 12873880
-
Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study.Br J Dermatol. 2018 Dec;179(6):1322-1328. doi: 10.1111/bjd.17073. Epub 2018 Oct 12. Br J Dermatol. 2018. PMID: 30098016
-
Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.Arch Dermatol. 2007 Jan;143(1):45-50. doi: 10.1001/archderm.143.1.45. Arch Dermatol. 2007. PMID: 17224541
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. J Am Acad Dermatol. 2014. PMID: 24438969 Review.
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review.
Cited by
-
In Vitro Antineoplastic and Antiviral Activity and In Vivo Toxicity of Geum urbanum L. Extracts.Molecules. 2021 Dec 31;27(1):245. doi: 10.3390/molecules27010245. Molecules. 2021. PMID: 35011479 Free PMC article.
-
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.Biomark Res. 2014 Sep 8;2:16. doi: 10.1186/2050-7771-2-16. eCollection 2014. Biomark Res. 2014. PMID: 25279222 Free PMC article.
-
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.Curr Hematol Malig Rep. 2023 Jun;18(3):83-88. doi: 10.1007/s11899-023-00692-w. Epub 2023 Apr 5. Curr Hematol Malig Rep. 2023. PMID: 37017872 Review.
-
Cutaneous T-cell lymphomas may require an exception to the ABHH consensus regarding empiric vancomycin use in febrile neutropenia.Hematol Transfus Cell Ther. 2025 Jul-Sep;47(3):103844. doi: 10.1016/j.htct.2025.103844. Epub 2025 May 17. Hematol Transfus Cell Ther. 2025. PMID: 40382880 Free PMC article. No abstract available.
-
Narrowband ultraviolet B response in cutaneous T-cell lymphoma is characterized by increased bacterial diversity and reduced Staphylococcus aureus and Staphylococcus lugdunensis.Front Immunol. 2022 Nov 11;13:1022093. doi: 10.3389/fimmu.2022.1022093. eCollection 2022. Front Immunol. 2022. PMID: 36439132 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical